PAVmed (PAVM) Gets a Buy Rating from Maxim Group

By Ryan Adsit

In a report released today, Anthony Vendetti from Maxim Group reiterated a Buy rating on PAVmed (PAVMResearch Report), with a price target of $5.00. The company’s shares closed last Friday at $2.34.

According to TipRanks.com, Vendetti is a 4-star analyst with an average return of 3.8% and a 46.4% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Milestone Scientific, Ra Medical Systems, and Sensus Healthcare.

PAVmed has an analyst consensus of Moderate Buy, with a price target consensus of $5.00.

See today’s analyst top recommended stocks >>

Based on PAVmed’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $6.24 million. In comparison, last year the company had a GAAP net loss of $6.83 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

PAVmed, Inc. is a medical device company, which develops and commercializes a pipeline of medical products. Its product portfolio includes DisappEAR, PORTIO, Caldus, Carpx, NextCath, and NextFlo. The company was founded on June 26, 2014 and is headquartered in New York, NY.